Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer

NCT05519449 is registered in ClinicalTrials.gov with Janux Therapeutics as lead sponsor.

NCT NCT05519449
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05519449 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer
Lead sponsor
Janux Therapeutics
Phase
Phase 1
Overall status
Recruiting
Start date
September 15, 2022
Completion date
December 31, 2028
Enrollment
272 (estimated)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

castration resistant prostatic cancer, metastatic castration-resistant prostate cancer, prostate cancer